A major subject in the area of oncology, particularly in the setting of lung carcinoma therapy, is osimertinib T790M.This term, referring to a particular mutation in the epidermal growth factor receptor (epidermal growth factor receptor) gene, signifies a primary cause of non-small cell lung carcinoma (NSCLC) (NSCLC).The objective of this article is to offer a detailed review of osimertinib T790M, covering its consequences, therapeutic approaches, and current study.A secondary mutation known as osimertinib T790M occurs in about 50-60% of patients with epidermal growth factor receptor-mutated NSCLC who have developed resistance…
